Zobrazeno 1 - 10
of 91
pro vyhledávání: '"35"'
Publikováno v:
Cancer Research. 74:35-35
Circulating tumor cells (CTCs) are the tumor cells shed from the primary tumor tissues into the bloodstream or lymphatic vessels. These CTCs are considered to be emerging tools for the detection and prognosis of several types of metastatic cancers. A
Publikováno v:
Cancer Research. 81:1913-1913
It is not clear if pre-existing anti-virus immunity or multicycle treatment of oncolytic virus (OV) can affect the treatment outcome. This study is to investigate the impact of pre-existing anti Herpes Simplex Virus type-1 (HSV-1) immunity or multicy
Autor:
Nancy Tray, Karen Hiotis, Deborah Axelrod, Victor Ty, Judith D. Goldberg, Farbod Darvishian, Maryann Kwa, Yelena Novik, Sylvia Adams, Amber A. Guth, James L. Speyer, Adriana Heguy, Douglas K. Marks
Publikováno v:
Cancer Research. 80:OT1-01
BACKGROUND: Receptor activator of NF-kB (RANK) and its ligand (RANKL) have a well-established role in osteoclast-driven bone remodeling, however RANK/RANKL expression can also be seen on mammary epithelial cells and immune cells (IC). In breast cance
Autor:
E. Alonso, JA Perez-Fidalgo, Begoña Bermejo, Octavio Burgues, Ana Bosch, M Peña-Chilet, Jaime Ferrer, Gloria Ribas, A. Lluch, M. Martinez
Publikováno v:
Cancer Research. 73:P5-13
BACKGROUND AND OBJECTIVES: Breast cancer in very young patients (< 35 years) (BCVY) is an uncommon disease and when it occurs it usually has aggressive biological characteristics. Whether this effect is due to an overrepresentation of aggressive brea
Autor:
Ronald Linnartz, Shawnt Issakhanian, Karen A. McDonald, Richard S. Finn, S Hurvitz, Emmanuelle DiTomaso, NA O'Brien, Luo Tong, Raul Ayala, DJ Slamon, S Hirawat
Publikováno v:
Cancer Research. 73:PD1-5
Background: The selective mTORC1 inhibitor everolimus (RAD001/Affinitor®) has recently been approved, in combination with exemestane, for treatment of advanced hormone receptor positive breast cancer after demonstrating significantly improved progre
Publikováno v:
Cancer Research. 70:P2-06
Introduction: The incidence of breast cancer, the most common cancer in women, is very high in Western Countries and is increasing rapidly in the Third World. Yet, despite better screening, earlier diagnosis, and the development of new therapies, a c
Autor:
Pamela J. Maxwell, David Waugh, Stephen McQuaid, Ian G. Mills, Manuel Salto-Tellez, Chee Wee Ong, Muhammad A Alvi
Publikováno v:
Cancer Research. 78:1555-1555
Background: Accurate identification of Gleason score (GS) 3+4 prostate cancer patients with low risk of disease progression is an unmet challenge in treatment decision making. We investigated the potential of using integrative genomic profiling to im
Publikováno v:
Cancer Research. 78:2240-2240
Obesity and physical inactivity increase breast cancer risk, while the prevention of weight gain by diet and exercise can be protective. Numerous biological mechanisms are proposed to explain the beneficial effects of weight maintenance, including ch
Autor:
Aby Joiakim, Hyesook Kim, David A. Putt, Julia M. Santos, Alan A. Dombkowski, David L. Kaplan, Ben A. Rybicki
Publikováno v:
Cancer Research. 78:690-690
The blood prostate-specific antigen (PSA) assay is used for prostate cancer diagnosis but specificity of the assay is not satisfactory. Previously a combined PSA and GDF-15 (NAG-1) score was shown to improve specificity of prostate cancer detection.
Publikováno v:
Cancer Research. 76:454-454
Osteosarcoma (OS) is the most common highly malignant primary solid bone-tumor. Despite its relatively low incidence rate among overall cancers, it remains one of the most harmful primary malignant tumors in childhood and adolescence. Although some t